COPD

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.

COPD kills at rates rivaling heart failure and exceeding prostate and breast cancer, per a new study and US mortality data.

Voice changes may help detect asthma and COPD exacerbations early, supporting future remote disease monitoring.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.

Patients with chronic obstructive pulmonary disease (COPD) who smoke were less likely to receive tobacco dependence treatment (TDT) if they lived in rural areas or had longer travel times to care, highlighting persistent geographic disparities in access.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

The systemic immune response index outperformed other inflammatory markers in predicting chronic obstructive pulmonary disease (COPD).

Low birth weight is associated with an increased risk of chronic obstructive pulmonary disease (COPD), particularly among smokers, highlighting the impact of early-life factors on respiratory health.

The top 5 most-read chronic obstructive pulmonary disease (COPD) articles of 2024 covered topics such as inhaled medication risks, gabapentinoid use, and the link between high white blood cell counts and exacerbations.

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

The top 5 most-viewed content from this year's American Thoracic Society (ATS) 2024 International Conference featured an interview with Monica Kraft, MD, ASTF, and coverage of multiple respiratory and pulmonary medicine areas.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of cognitive impairment, with a notably higher likelihood of developing non-amnestic mild cognitive impairment.

Higher dietary magnesium intake is associated with a reduced risk of frailty in patients with chronic obstructive pulmonary disease (COPD), emphasizing its potential role in improving clinical outcomes.

While the Medicare Competitive Bidding Program reduced spending, it did not significantly impact supplemental oxygen use or clinical outcomes among patients with chronic obstructive pulmonary disease (COPD).

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report highlighted climate change, cardiovascular risk, and pulmonary hypertension.

Social isolation significantly increases the risk of mortality in patients with chronic obstructive pulmonary disease (COPD), highlighting the need for targeted interventions to address this issue.

Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.

Chronic obstructive pulmonary disease (COPD) burden remains high in underdeveloped regions of China despite a decline in related deaths, highlighting the need for targeted management and prevention strategies.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and chronic obstructive pulmonary disease (COPD).

The Noninvasive Ventilation Outcomes (NIVO) score is a reliable predictor of intensive care unit (ICU) mortality, 1-year mortality, and NIV failure in patients with acute exacerbations of COPD (AECOPD), offering valuable guidance for personalized patient management.

Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.